Cargando…

SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine

BACKGROUND: Starting in December 2019, the current pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confronts the world with an unprecedented challenge. With no vaccine or drug being currently available to control the pandemic spread, prevention and PCR (Polymerase...

Descripción completa

Detalles Bibliográficos
Autores principales: Marschner, Sebastian, Corradini, Stefanie, Rauch, Josefine, Zacharias, Richard, Sujic, Ana, Mayerle, Julia, Petru, Raluca, Grabein, Béatrice, Keppler, Oliver T., Boelke, Edwin, Belka, Claus, Niyazi, Maximilian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344028/
https://www.ncbi.nlm.nih.gov/pubmed/32646505
http://dx.doi.org/10.1186/s13014-020-01609-0
_version_ 1783555870026629120
author Marschner, Sebastian
Corradini, Stefanie
Rauch, Josefine
Zacharias, Richard
Sujic, Ana
Mayerle, Julia
Petru, Raluca
Grabein, Béatrice
Keppler, Oliver T.
Boelke, Edwin
Belka, Claus
Niyazi, Maximilian
author_facet Marschner, Sebastian
Corradini, Stefanie
Rauch, Josefine
Zacharias, Richard
Sujic, Ana
Mayerle, Julia
Petru, Raluca
Grabein, Béatrice
Keppler, Oliver T.
Boelke, Edwin
Belka, Claus
Niyazi, Maximilian
author_sort Marschner, Sebastian
collection PubMed
description BACKGROUND: Starting in December 2019, the current pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confronts the world with an unprecedented challenge. With no vaccine or drug being currently available to control the pandemic spread, prevention and PCR (Polymerase chain reaction) testing becomes a crucial pillar of medical systems. Aim of the present study was to report on the first results of the measures taken in a large German Department of Radiation Oncology, including PCR testing of asymptomatic cancer patients. METHODS: Pandemic-adapted hygiene regulations and prevention measures for patients and staff were implemented. A visiting ban on both wards was implemented from the beginning and medical staff and patients were required to wear face masks at all times. The waiting rooms were rearranged to ensure distance between patients of at least 1.5 m. Clinical follow up was mainly done by telephone and all patients had to complete a questionnaire regarding symptoms and contacts with COVID-19 patients before entering our department. Educational documents were created for patients to raise awareness of symptoms and avoidance strategies for interactions with other people. Indications for therapy and fractionation schemes were adapted when possible. In a subsequent step, all new asymptomatic patients were tested via nasopharyngeal swab at our screening station shortly before their simulation CT. RESULTS: All these measures and implementations have been well accepted semiquantitatively measured by the consent received from patients and staff. Regarding the PCR testing, only 1 out of 139 asymptomatic patients of our cohort so far tested positive for SARS-CoV-2, reflecting a prevalence of 0.72% in this cancer patient population. Up to this point no staff members was tested positive. The start of the treatment for the PCR-positive patient was deferred for 2 weeks. CONCLUSION: Due to the pandemic-adapted implementations, our department seems well prepared during this crisis. The initial screening helps to identify asymptomatic COVID-19 patients in order to protect other patients and our staff from infection and the observed PCR prevalence is in line with comparable studies. A regular PCR testing (e.g. twice a week) of all patients and staff would in principle be desirable but is limited due to testing capacities at present.
format Online
Article
Text
id pubmed-7344028
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73440282020-07-09 SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine Marschner, Sebastian Corradini, Stefanie Rauch, Josefine Zacharias, Richard Sujic, Ana Mayerle, Julia Petru, Raluca Grabein, Béatrice Keppler, Oliver T. Boelke, Edwin Belka, Claus Niyazi, Maximilian Radiat Oncol Research BACKGROUND: Starting in December 2019, the current pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confronts the world with an unprecedented challenge. With no vaccine or drug being currently available to control the pandemic spread, prevention and PCR (Polymerase chain reaction) testing becomes a crucial pillar of medical systems. Aim of the present study was to report on the first results of the measures taken in a large German Department of Radiation Oncology, including PCR testing of asymptomatic cancer patients. METHODS: Pandemic-adapted hygiene regulations and prevention measures for patients and staff were implemented. A visiting ban on both wards was implemented from the beginning and medical staff and patients were required to wear face masks at all times. The waiting rooms were rearranged to ensure distance between patients of at least 1.5 m. Clinical follow up was mainly done by telephone and all patients had to complete a questionnaire regarding symptoms and contacts with COVID-19 patients before entering our department. Educational documents were created for patients to raise awareness of symptoms and avoidance strategies for interactions with other people. Indications for therapy and fractionation schemes were adapted when possible. In a subsequent step, all new asymptomatic patients were tested via nasopharyngeal swab at our screening station shortly before their simulation CT. RESULTS: All these measures and implementations have been well accepted semiquantitatively measured by the consent received from patients and staff. Regarding the PCR testing, only 1 out of 139 asymptomatic patients of our cohort so far tested positive for SARS-CoV-2, reflecting a prevalence of 0.72% in this cancer patient population. Up to this point no staff members was tested positive. The start of the treatment for the PCR-positive patient was deferred for 2 weeks. CONCLUSION: Due to the pandemic-adapted implementations, our department seems well prepared during this crisis. The initial screening helps to identify asymptomatic COVID-19 patients in order to protect other patients and our staff from infection and the observed PCR prevalence is in line with comparable studies. A regular PCR testing (e.g. twice a week) of all patients and staff would in principle be desirable but is limited due to testing capacities at present. BioMed Central 2020-07-09 /pmc/articles/PMC7344028/ /pubmed/32646505 http://dx.doi.org/10.1186/s13014-020-01609-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Marschner, Sebastian
Corradini, Stefanie
Rauch, Josefine
Zacharias, Richard
Sujic, Ana
Mayerle, Julia
Petru, Raluca
Grabein, Béatrice
Keppler, Oliver T.
Boelke, Edwin
Belka, Claus
Niyazi, Maximilian
SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine
title SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine
title_full SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine
title_fullStr SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine
title_full_unstemmed SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine
title_short SARS-CoV-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine
title_sort sars-cov-2 prevalence in an asymptomatic cancer cohort - results and consequences for clinical routine
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344028/
https://www.ncbi.nlm.nih.gov/pubmed/32646505
http://dx.doi.org/10.1186/s13014-020-01609-0
work_keys_str_mv AT marschnersebastian sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine
AT corradinistefanie sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine
AT rauchjosefine sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine
AT zachariasrichard sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine
AT sujicana sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine
AT mayerlejulia sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine
AT petruraluca sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine
AT grabeinbeatrice sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine
AT kepplerolivert sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine
AT boelkeedwin sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine
AT belkaclaus sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine
AT niyazimaximilian sarscov2prevalenceinanasymptomaticcancercohortresultsandconsequencesforclinicalroutine